Journal of Translational Medicine,
Год журнала:
2025,
Номер
23(1)
Опубликована: Март 20, 2025
Studies
have
shown
that
in
the
pathogenesis
of
head
and
neck
squamous
cell
carcinoma,
immune
circulation
obstruction
caused
by
various
factors
including
metabolic
abnormalities,
gene
mutations,
matrix
barrier,
is
a
critical
factor
for
induction
tumor
development
progression.
Therefore,
immunotherapy
strategy
killing
carcinoma
cells
an
enhanced
mechanism
has
attracted
much
attention.
In
addition,
rapid
new
nucleic
acid
drug
therapy,
such
as
mRNA,
oligonucleotide
small
guide
RNA
(sgRNA),
taken
(immune
checkpoint
inhibitors,
vaccines,
cellular
immunotherapy,
cytokines
adjuvants,
etc.)
to
level.
The
combination
therapy
with
developed
its
therapeutic
properties
brought
direction
diagnosis
treatment
two
had
considerable
curative
effect
patients
refractory/recurrent
carcinoma.
this
review,
we
summarized
latest
progress
applied
conventional
discussed
action
efficacy,
looked
into
future
trend.
Vaccines,
Год журнала:
2024,
Номер
12(2), С. 186 - 186
Опубликована: Фев. 12, 2024
In
recent
years,
lipid
nanoparticles
(LNPs)
have
attracted
extensive
attention
in
tumor
immunotherapy.
Targeting
immune
cells
cancer
therapy
has
become
a
strategy
of
great
research
interest.
mRNA
vaccines
are
potential
choice
for
immunotherapy,
due
to
their
ability
directly
encode
antigen
proteins
and
stimulate
strong
response.
However,
the
mode
delivery
lack
stability
key
issues
limiting
its
application.
LNPs
an
excellent
carrier,
structural
biocompatibility
make
them
effective
means
delivering
specific
targets.
This
study
summarizes
progress
LNP
carrier-assisted
targeted
controlled
release
immunity.
The
role
improving
stability,
immunogenicity,
targeting
is
discussed.
review
aims
systematically
summarize
latest
immunity
provide
new
ideas
strategies
as
well
more
treatment
plans
patients.
Trends in Pharmacological Sciences,
Год журнала:
2024,
Номер
45(5), С. 406 - 418
Опубликована: Апрель 12, 2024
T
cells
modified
to
express
intelligently
designed
chimeric
antigen
receptors
(CARs)
are
exceptionally
powerful
therapeutic
agents
for
relapsed
and
refractory
blood
cancers
have
the
potential
revolutionize
therapy
many
other
diseases.
To
circumvent
complexity
cost
associated
with
broad-scale
implementation
of
ex
vivo
manufactured
adoptive
cell
products,
alternative
strategies
generate
CAR
in
by
direct
infusion
nanoparticle-formulated
nucleic
acids
or
engineered
viral
vectors
under
development
received
a
great
deal
attention
past
few
years.
Here,
we
outline
manufacturing
process
as
motivating
framework
discuss
emerging
data
from
preclinical
models
highlight
potency
approach,
applicability
new
disease
indications,
remaining
challenges
clinical
readiness,
including
delivery
specificity,
long
term
efficacy,
safety.
Abstract
Significant
advancements
have
been
made
in
the
application
of
chimeric
antigen
receptor
(CAR)-T
treatment
for
blood
cancers
during
previous
ten
years.
However,
its
effectiveness
treating
solid
tumors
is
still
lacking,
necessitating
exploration
alternative
immunotherapies
that
can
overcome
significant
challenges
faced
by
current
CAR-T
cells.
CAR-based
immunotherapy
against
shows
promise
with
emergence
macrophages,
which
possess
robust
phagocytic
abilities,
antigen-presenting
functions,
and
ability
to
modify
tumor
microenvironment
stimulate
adaptive
responses.
This
paper
presents
a
thorough
examination
latest
progress
CAR-M
therapy,
covering
both
basic
scientific
studies
clinical
trials.
study
examines
primary
obstacles
hindering
realization
complete
potential
as
well
strategies
be
employed
these
hurdles.
With
revolutionary
technologies
like
situ
genetic
modification,
synthetic
biology
techniques,
biomaterial-supported
gene
transfer,
provide
wider
array
resources
manipulating
tumor-associated
we
suggest
combining
advanced
methods
will
result
creation
new
era
therapy
demonstrates
improved
efficacy,
safety,
availability.
Graphical
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Март 20, 2024
Immune
checkpoint
molecules
are
a
group
of
expressed
on
the
surface
immune
cells
that
primarily
regulate
their
homeostasis.
Chimeric
antigen
receptor
(CAR)
T
cell
therapy
is
an
immunotherapeutic
technology
realizes
tumor-targeted
killing
by
constructing
synthetic
expressing
specific
antigens
through
biotechnology.
Currently,
CAR-T
has
achieved
good
efficacy
in
non-solid
tumors,
but
its
treatment
solid
tumors
not
yielded
desired
results.
inhibitors
(ICIs)
combined
with
novel
combination
high
expectations
to
defeat
tumors.
This
review
addresses
challenges
and
this
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Ноя. 14, 2024
Abstract
In
the
last
decade,
messenger
ribonucleic
acid
(mRNA)-based
drugs
have
gained
great
interest
in
both
immunotherapy
and
non-immunogenic
applications.
This
surge
can
be
largely
attributed
to
demonstration
of
distinct
advantages
offered
by
various
mRNA
molecules,
alongside
rapid
advancements
nucleic
delivery
systems.
It
is
noteworthy
that
immunogenicity
presents
a
double-edged
sword.
context
immunotherapy,
extra
supplementation
adjuvant
generally
required
for
induction
robust
immune
responses.
Conversely,
non-immunotherapeutic
scenarios,
activation
unwanted
considering
host
tolerability
high
expression
demand
mRNA-encoded
functional
proteins.
Herein,
mainly
focused
on
linear
non-replicating
mRNA,
we
overview
preclinical
clinical
progress
prospects
medicines
encompassing
vaccines
other
therapeutics.
We
also
highlight
importance
focusing
host-specific
variations,
including
age,
gender,
pathological
condition,
concurrent
medication
individual
patient,
maximized
efficacy
safety
upon
administration.
Furthermore,
deliberate
potential
challenges
may
encounter
realm
disease
treatment,
current
endeavors
improvement,
as
well
application
future
advancements.
Overall,
this
review
aims
present
comprehensive
understanding
mRNA-based
therapies
while
illuminating
prospective
development
drugs.
European Journal of Pharmaceutics and Biopharmaceutics,
Год журнала:
2024,
Номер
197, С. 114222 - 114222
Опубликована: Фев. 20, 2024
Lipid
nanoparticles
(LNPs)
employing
ionizable
lipids
are
the
most
advanced
technology
for
delivery
of
RNA,
notably
mRNA,
to
cells.
LNPs
represent
well-defined
core–shell
particles
with
efficient
nucleic
acid
encapsulation,
low
immunogenicity
and
enhanced
efficacy.
While
much
is
known
about
structure
activity
LNPs,
less
attention
given
timing
LNP
uptake,
cytosolic
transfer
protein
expression.
However,
kinetics
a
key
factor
determining
efficiency.
Hence
quantitative
insight
into
multi-cascaded
pathway
interest
elucidate
mechanism
delivery.
Here,
we
review
experiments
as
well
theoretical
modeling
mRNA-release
We
describe
sequence
stochastic
processes
mathematical
model
subsequent
translation
from
mRNA.
compile
probabilities
numbers
obtained
time
resolved
microscopy.
Specifically,
live-cell
imaging
on
single
cell
arrays
(LISCA)
allows
high-throughput
acquisition
thousands
individual
GFP
reporter
expression
courses.
The
traces
yield
distribution
mRNA
life-times,
rates
onset.
Correlation
analysis
reveals
an
inverse
dependence
gene
efficiency
transfection
onset-times.
Finally,
discuss
why
release
critical
in
context
codelivery
multiple
species
case
co-expression
or
CRISPR/Cas
editing.
Journal of Controlled Release,
Год журнала:
2025,
Номер
379, С. 236 - 250
Опубликована: Янв. 11, 2025
The
recent
approval
of
pembrolizumab
in
recurrent
or
metastatic
cervical
cancer
warrants
further
investigations
into
the
usefulness
immunotherapies
for
more
durable
and
less
radical
interventions.
In
this
study,
targeting
potential
anti-PD-L1-functionalized
immunoliposomes
was
tested
a
3D
vitro
cancer-on-a-chip
model.
Immunolipsomes
were
synthesized
decorated
externally
with
monovalent
anti-PD-L1
Fab'
fragments
commercially
available
atezolizumab.
Cervical
cell
lines
varying
levels
PD-L1
expression
cultured
as
spheroids
embedded
collagen
I
matrix,
treated
under
flow
culture
media.
Flow
cytometry
live-cell
confocal
imaging
used
to
measure
interactions
uptake
untargeted
liposomes
panel
lines.
retained
specific
functionality
regardless
protein
corona
formation
high
serum
environments.
As
such,
expressing
preferentially
internalized
environment
extracellular
matrix
present,
while
low
PD-L1-expressing
showed
no
preference
either
formulation.
Importantly,
treatments
performed
monolayer
cultures
(on
plastic)
differences
between
immuno-
liposome
uptake,
including
way
which
endocytosed
are
trafficked
subcellularly.
This
study
demonstrates
importance
both
active
passive
accumulation
strategies
achieve
nanoparticle
targeting.
Immunoliposomes
remain
promising
platform
development
targeted
nanotherapies
against
cancers.
However,
initial
functional
tests
did
not
translate
directly
biological
performance
should
be
kept
mind
future
formulations.
Furthermore,
model
developed
appeared
useful
visualizing
3D,
live
tissue
represents
cost-effective
reproducible
studies.
